Mechanistic Heterogeneity in Type 2 Diabetes and Hypertension Comorbidity Revealed with Partitioned Polygenic Scores

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research has been conducted using the UK Biobank Resource under application number 236. This project was in part funded by the Agence Nationale de la Recherche under the Programme d'Investissement d'Avenir (PreciDIAB, ANR-18-IBHU-0001 and RHU PreciNASH ANR-16-RHUS-0006), by the European Union through the "Fonds Europeen de Developpement Regional" (FEDER), by the "Conseil Regional des Hauts-de-France" (Hauts-de-France Regional Council), by the "Metropole Europeenne de Lille" (MEL, European Metropolis of Lille), and by the European Research Council (ERC OpiO - 101043671, to AB) The authors would like to thank all the investigators from different consortia that built and shared the GWAS meta-analysis, eQTLs, and scATAC-seq atlases used in this study, as well as the UK Biobank participants and dedicated staff.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The GWAS used in this study are all publicly available and listed in Supplementary Table 4. The UK Biobank Resource (UKB, https://ukbiobank.ac.uk/) was accessed using the Application Number 236. GTEx (https://www.gtexportal.org/home/datasets/) and TIGER (http://tiger.bsc.es/) eQTLs are publicly available. The ATAC-seq data from CATLAS are publicly available http://catlas.org/humanenhancer/. Data from the ABOS cohort are not publicly available, as the study is ongoing. The Biological Atlas of Severe Obesity (Atlas Biologique de l'Obesité Sévère [ABOS]) cohort (ClinicalTrials.gov: NCT01129297) is an ongoing prospective study that aims to identify the determinants of bariatric surgery outcomes. Patients were recruited at the Centre Hospitalier Universitaire de Lille (France), as previously described in DOI: 10.1097/SLA.0000000000000945, DOI: 10.1016/S2213-8587(22)00005-5, and DOI: 10.1038/s41467-024-51078-2. All human procedures were ethically approved by the Comité de Protection des Personnes Nord Ouest IV or by the ethics committee of Liège University Hospital. The analysis performed in this study aligned with the original scopes and objectives of the ABOS and Liège cohort studies; therefore, no additional ethical approval was requested.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes